US 11,723,864 B2
Antimicrobial and anti-inflammatory compositions
Carolyn L. Cannon, College Station, TX (US); Parth N. Shah, College Station, TX (US); Justin A. Smolen, College Station, TX (US); Hugh D. Smyth, Westlake, TX (US); Ashkan K. Yazdi, Austin, TX (US); and Matthew J. Herpin, Austin, TX (US)
Assigned to The Texas A&M University System, College Station, TX (US); and The Board of Regents of the University of Texas System, Austin, TX (US)
Appl. No. 15/576,485
Filed by The Texas A&M University System, College Station, TX (US); and The Board of Regents of the University of Texas System, Austin, TX (US)
PCT Filed May 29, 2016, PCT No. PCT/US2016/034906
§ 371(c)(1), (2) Date Nov. 22, 2017,
PCT Pub. No. WO2016/196401, PCT Pub. Date Dec. 8, 2016.
Claims priority of provisional application 62/168,561, filed on May 29, 2015.
Prior Publication US 2018/0207093 A1, Jul. 26, 2018
Int. Cl. A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61P 29/00 (2006.01); A61K 31/19 (2006.01); A61K 45/06 (2006.01)
CPC A61K 9/0078 (2013.01) [A61K 9/0075 (2013.01); A61K 31/19 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61P 29/00 (2018.01)] 6 Claims
 
1. A dry powder inhaler composition for treating or ameliorating inflammation and/or treating a disease in a subject in need thereof, wherein the composition consists of a micronized formulation of non-steroidal anti-inflammatory drug (NSAID) particles, wherein the NSAID particles and composition are carrier-free, wherein the NSAID particles consist of pure and excipient-free, undiluted NSAID, wherein the composition has a respirable fraction (RF) value of at least 50% and wherein the NSAID possesses anti-inflammatory and antimicrobial activities.